Loading organizations...
§ Private Profile · Trento, Italy
Biotechnology company developing gene editing tools for genetic diseases, initially eye diseases, focused on precise CRISPR-Cas9.
Alia Therapeutics is a biotechnology company based in Milan and Trento, Italy, that develops advanced CRISPR-based gene-editing medicines to treat severe genetic diseases. The startup focuses on engineering high-fidelity nucleases, specifically SpCas9 variants, to enhance the precision and safety of clinical applications by minimizing unwanted off-target DNA mutations. To support its proprietary research and development pipeline, the company has raised a total of $6.26 million in venture capital funding across multiple rounds. This financial backing includes investments from prominent institutional venture capital firms such as Sofinnova Partners, Indaco Bio, Atlante Seed, and BiovelocITA. The organization recently appointed Letizia Goretti as chief executive officer to lead its initial clinical focus on rare ophthalmic conditions. Alia Therapeutics was founded in 2018 as a spin-off from the University of Trento by Anna Cereseto, Gianluca Petris, and Antonio Casini.
Alia Therapeutics has raised $6.0M across 2 funding rounds.
Alia Therapeutics has raised $6.0M in total across 2 funding rounds.
Alia Therapeutics has raised $6.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2023 | $5M Seed | Soffinova Partners | Atlas Venture, EQT Life Sciences, Pivotal BioVenture Partners, SR ONE, Banca Profilo, Banor SIM, Elizabeth Robinson | Announced |
| Apr 1, 2019 | $1M Seed | — | Soffinova Partners | Announced |
Alia Therapeutics has raised $6.0M in total across 2 funding rounds.
Alia Therapeutics's investors include Soffinova Partners, Atlas Venture, EQT Life Sciences, Pivotal bioVenture Partners, SR One, Banca Profilo, Banor SIM, Elizabeth Robinson.
Alia Therapeutics is a biotechnology company developing next-generation CRISPR-based gene editing therapies to treat genetic diseases, with a primary focus on autosomal-dominant retinitis pigmentosa and other inherited disorders.[1][2][4] The company optimizes CRISPR tools for enhanced safety, precision, and efficiency, targeting previously inaccessible genomic sites to enable "one-and-done" treatments that cure diseases at their roots.[1][2] Currently in the pre-clinical stage with seed funding, Alia serves patients with rare genetic conditions, addressing unmet needs in in vivo gene editing for retinal degeneration and beyond.[1][3][4]
Alia Therapeutics was founded in 2018 as a spin-off from the University of Trento in Trento, Trentino-Alto Adige, Italy, and was accelerated through BiovelocITA, Italy’s first biotechnology accelerator co-founded by Sofinnova Partners.[4][5] Emerging from academic research, the company initially targeted safer on-target in vivo gene editing for retinal degeneration, later expanding to engineer novel microbiome-derived CRISPR nucleases for broader genetic disease applications.[4][5] Key early support came from partners like Sofinnova Partners via their Telethon strategy, marking pivotal traction in translating Italian science to global therapeutics.[4]
Alia's edge lies in its advanced CRISPR engineering, distinguishing it from competitors like Caribou Biosciences and Poseida Therapeutics:
Alia rides the wave of CRISPR evolution, capitalizing on proven efficacy of genetic medicines amid surging demand for precise, in vivo therapies for rare diseases.[2][3] Its timing aligns with regulatory momentum (e.g., FDA approvals for CRISPR therapies) and advances in microbiome genomics, positioning it to influence the shift from ex vivo to accessible in vivo editing.[1][5] Market forces like aging populations driving retinal disease prevalence and investor focus on Italian biotech hubs (via accelerators like BiovelocITA) favor Alia, amplifying Europe's role in global gene editing innovation.[4]
Alia is poised for Series A funding and first-in-human trials, leveraging its pre-clinical momentum to advance its retinitis pigmentosa program into clinic within 2-3 years.[1][4] Trends like AI-optimized nucleases and expanded microbiome screening will accelerate its pipeline, potentially disrupting competitors by targeting extrahepatic tissues.[3][5] As it scales partnerships and influences ecosystem standards for safer CRISPR, Alia's vision to revolutionize genetic medicine could redefine cures for intractable disorders, building directly on its foundational commitment to patients and precision.[2]